# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Stephens & Co. analyst Mason Carrico reiterates Castle Biosciences (NASDAQ:CSTL) with a Overweight and maintains $37 pri...
Baird analyst Catherine Ramsey maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and raises the price target from...
Castle Biosciences (NASDAQ:CSTL) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $(...